Treatment of a population based sample of men diagnosed with testicular cancer in the United States

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 6, 2009, Pages 604-610

  Osswald, Michael ^a   Harlan, Linda C ^b   Penson, David ^c   Stevens, Jennifer L ^d   Clegg, Limin X ^e  

^a Lackland Air Force Base ^*  (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Guideline adherence; Radiotherapy; Surgery; Testicular cancer; Treatment

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; HUMAN; INFANT; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEMINOMA; TESTIS CANCER; UNITED STATES;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GERMINOMA; GUIDELINE ADHERENCE; HUMANS; INFANT; INFANT, NEWBORN; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY; RETROPERITONEAL SPACE; SEER PROGRAM; SEMINOMA; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 70350519358     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.06.004     Document Type: Article

References (17)

1. American Cancer Society. Cancer facts and figures 2008 (2007), American Cancer Society, Atlanta (GA) 4
2. McGlynn K.A., Devesa S.S., Graubard B.I., et al. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol 23 (2005) 5757-5761
3. National Cancer Institute. SEER cancer statistics review 1975-2003. http://seer.cancer.gov/csr/1975_2003/results_merged/sect_25_testis.pdf Accessed August 29, 2008
4. National Cancer Institute. SEER Program: Comparative staging guide for cancer. http://seer.cancer.gov/manuals/historic/comp_stage1.1.pdf Accessed August 29, 2008
5. Shah B.V., Barnwall B.G., and Bieler G.S. SUDAAN (1997), Research Triangle Institute, Research Triangle Park (NC) 10-11
6. Schmoli H.J., Souchon R., Krege S., et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Onc 15 (2004) 1377-1399
7. Oliver R.T.D., Mason M.D., Mead G.M., et al. Radiotherapy vs. single-dose carboplatin in adjuvant treatment of Stage I seminoma: A randomized trial. Lancet 366 (2005) 293-300
8. Segal R. Surveillance programs for Stage I nonseminomatous germ cell tumors of the testis. Urol Oncol 24 (2006) 68-74
9. Steele G.S., Richie J.P., Stewart A.K., et al. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer 86 (1999) 2171-2183
10. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Testicular cancer. http://www.nccn.org/professionals/physicians_gls/PDF/testicular.pdf Accessed August 29, 2008
11. Gilbert D.C., Norman A.R., Nicholl J., et al. Treating Stage I nonseminomatous germ cell tumors with a single cycle of chemotherapy. BJU Int 98 (2006) 67-69
12. Mezvrishvili Z., and Managadze L. One cycle of bleomycin, etoposide, and cisplatin plus two cycles of etoposide and cisplatin chemotherapy in selected patients with low-volume Stage II nonseminomatous germ cell tumor of the testis. Urol Int 75 (2005) 304-308
13. Oliver R.T.D., Ong J., Shamash J., et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance vs. patients with Stage I nonseminoma treated with adjuvant chemotherapy. Urology 63 (2004) 556-561
14. Horwich A., Sleijfer D.B., Fossa S.D., et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15 (1997) 1844-1852
15. Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol 11 (1993) 593-595
16. Ozer H., Armitage J.O., Bennett C.L., et al. American Society of Clinical Oncology 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Clinical Oncology, Growth Factors Expert Panel. J Clin Oncol 18 (2000) 3558-3585
17. van Dijk, Steyerberg E.W., and Habbema J.D.F. Survival of nonseminomatous germ cell cancer patients according to the IGGG classification: An update based on meta-analysis. Eur J Cancer 42 (2006) 820-826